In a report released on February 27, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $8.00.
Whitney Ijem has given his Buy rating due to a combination of factors including the anticipated data from Taysha Gene Therapies’ clinical trials and the company’s financial outlook. The upcoming safety and efficacy data from Cohort 2, along with longer-term follow-up data from Cohort 1, are key elements that could potentially drive the stock’s performance. Importantly, no treatment-related serious adverse events or dose-limiting toxicities have been reported, which is a positive indicator for the ongoing trials.
Additionally, Taysha Gene Therapies has been proactive in its regulatory interactions, maintaining ongoing meetings with the FDA, which is crucial given the RMAT designation for TSHA-102. The company’s financial position is also strong, with $139.0 million in cash at the end of 4Q24, expected to sustain operations into 4Q26. These factors, combined with the planned update on pivotal trial design and primary endpoint, support the reiteration of the Buy rating.
According to TipRanks, Ijem is an analyst with an average return of -1.7% and a 39.04% success rate. Ijem covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Vertex Pharmaceuticals, and Arcturus Therapeutics.
In another report released on February 27, JMP Securities also maintained a Buy rating on the stock with a $5.00 price target.